A nurse is collecting data from a client who has been taking esomeprazole for several months

1. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, Hanlon JT. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370:173–184. [PubMed] [Google Scholar]

2. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107–1116. [PubMed] [Google Scholar]

3. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–2012. [PubMed] [Google Scholar]

4. Routledge PA, Mahony MSO, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004;57:121–126. [PMC free article] [PubMed] [Google Scholar]

5. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716–2724. [PubMed] [Google Scholar]

6. Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening tool of older person's prescriptions) and START (screening tool to alert doctors to right treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46:72–83. [PubMed] [Google Scholar]

7. Pyszka LL, Seys Ranola TM, Milhans SM. Identification of inappropriate prescribing in geriatrics at a veterans affairs hospital using STOPP/START screening tools. Consult Pharm. 2010;25:365–373. [PubMed] [Google Scholar]

8. Gallagher P, Lang P, Cherubini A, Topinková E, Cruz-Jentoft A, Montero Errasquín B, et al. Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals. Eur J Clin Pharmacol. 2011;67:1175–1188. [PubMed] [Google Scholar]

9. Liu C-L, Peng L-N, Chen Y-T, Lin M-H, Liu L-K, Chen L-K. Potentially inappropriate prescribing (IP) for elderly medical inpatients in Taiwan: a hospital-based study. Arch Gerontol Geriatr. 2012;55:148–151. [PubMed] [Google Scholar]

10. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 2010;69:543–552. [PMC free article] [PubMed] [Google Scholar]

11. Hamilton H, Gallagher P, Ryan C, Byrne S, O'Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 2011;171:1013–1019. [PubMed] [Google Scholar]

12. Naughton C, Bennett K, Feely J. Prevalence of chronic disease in the elderly based on a national pharmacy claims database. Age Ageing. 2006;35:633–636. [PubMed] [Google Scholar]

13. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) Classification Index. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2010. [Google Scholar]

14. Parry G, Cline A, Goldman D. Deciphering harm measurement. JAMA. 2012;307:2155–2156. [PubMed] [Google Scholar]

15. Jarernsiripornkul N, Krska J, Capps PA, Richards RM, Lee A. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol. 2002;53:318–325. [PMC free article] [PubMed] [Google Scholar]

16. Chrischilles EA, VanGilder R, Wright K, Kelly M, Wallace RB. Inappropriate medication use as a risk factor for self-reported adverse drug effects in older adults. J Am Geriatr Soc. 2009;57:1000–1006. [PubMed] [Google Scholar]

17. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Seger DL, Shu K, Federico F, Leape LL, Bates DW. Adverse drug events in ambulatory care. N Engl J Med. 2003;348:1556–1564. [PubMed] [Google Scholar]

18. Landis J, Koch G. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174. [PubMed] [Google Scholar]

19. The EuroQol Group. EuroQol- A new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208. [PubMed] [Google Scholar]

20. Grundy E, Holt G. The socioeconomic status of older adults: how should we measure it in studies of health inequalities? J Epidemiol Community Health. 2001;55:895–904. [PMC free article] [PubMed] [Google Scholar]

21. Charlson M, Pompei P, Ales K, MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. [PubMed] [Google Scholar]

22. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32:705–714. [PubMed] [Google Scholar]

23. Lubben J, Blozik E, Gillmann G, Iliffe S, von Renteln Kruse W, Beck JC, Stuck AE. Performance of an abbreviated version of the lubben social network scale among three european community-dwelling older adult populations. Gerontologist. 2006;46:503–513. [PubMed] [Google Scholar]

24. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10:3–12. [PubMed] [Google Scholar]

25. Morisky DE, Ward HJ, Liu KY. Self-reported medication taking behaviour: a valid indicator for assessing compliance. In 129th American Public Health Association Meeting. Atlanta, 2001.

26. Hanlon JT, Schmader KE. What types of inappropriate prescribing predict adverse drug reactions in older adults? Ann Pharmacother. 2010;44:1110–1111. [PMC free article] [PubMed] [Google Scholar]

27. Lund BC, Carnahan RM, Egge JA, Chrischilles EA, Kaboli PJ. Inappropriate prescribing predicts adverse drug events in older adults. Ann Pharmacother. 2010;44:957–963. [PubMed] [Google Scholar]

28. Gelman A, Hall J. Data Analysis Using Regression and Multilevel/Hierarchial Models. London: Cambridge University Press; 2003. [Google Scholar]

29. Lai KC, Lam SK, Chu KM, Wong BCY, Hui WM, Hu WHC, Lau GKK, Wong WM, Yuen MF, Chan AOO, Lai CL, Wong J. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033–2038. [PubMed] [Google Scholar]

30. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–19. [PMC free article] [PubMed] [Google Scholar]

31. Shehab N, Sperling LS, Keqler SR, Budnitz DS. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Arch Intern Med. 2010;170:1926–1933. [PubMed] [Google Scholar]

32. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, Pirmohamed M. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63:136–147. [PMC free article] [PubMed] [Google Scholar]

33. Fick DM, Waller JL, Maclean JR, Heuvel RV, Tadlock JG, Gottlieb M, Cangialose CB. Potentially inappropriate medication use in a medicare managed care population: association with higher costs and utilization. J Manag Care Pharm. 2001;7:407–413. [Google Scholar]

34. Walters S, Brazier J. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14:1523–1532. [PubMed] [Google Scholar]

35. Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes. 2006;4:70–75. [PMC free article] [PubMed] [Google Scholar]

36. Perera S, Studenski S, Chandler JM, Guralnik JM. Magnitude and patterns of decline in health and function in 1 year affect subsequent 5-year survival. J Gerontol A Biol Sci Med Sci. 2005;60:894–900. [PubMed] [Google Scholar]

37. Guthrie B, McCowan C, Davey P, Simpson CR, Dreischulte T, Barnett K. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. BMJ. 2011;342:d3514. [PubMed] [Google Scholar]

38. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010;170:1648–1654. [PubMed] [Google Scholar]

39. Clyne B, Bradley M, Smith SM, Hughes CM, Motterlini N, Clear D, McDonnell R, Williams D, Fahey T OPTI-SCRIPT Study Team. Effectiveness of medicines review with web-based pharmaceutical treatment algorithms in reducing potentially inappropriate prescribing in older people in primary care: a cluster randomized trial (OPTI-SCRIPT study protocol) BMC Trials. 2013;14:72. [PMC free article] [PubMed] [Google Scholar]

40. Weingart SN, Gandhi TK, Seger AC, Seger DL, Borus J, Burdick E, Leape LL, Bates DW. Patient-reported medication symptoms in primary care. Arch Intern Med. 2005;165:234–240. [PubMed] [Google Scholar]

41. Steinman MA, Handler SM, Gurwitz JH, Schiff GD, Covinsky KE. Beyond the prescription: medication monitoring and adverse drug events in older adults. J Am Geriatr Soc. 2011;59:1513–1520. [PMC free article] [PubMed] [Google Scholar]

Page 2

The 10 most frequently prescribed PIP indicators as per STOPP criteria

Criteria description	n	% (95% CI)
Cardiovascular system
β-adrenoceptor blocker with COPD (risk of increased bronchospasm)	28	3.10 (2.90, 3.29)
Calcium channel blockers with chronic constipation*	63	6.97 (6.55, 7.39)
Aspirin and warfarin without histamine H2-receptor antagonist (except cimetidine) or PPI (high risk of gastrointestinal bleeding)	23	2.54 (2.38, 2.71)
Aspirin with a past history of peptic ulcer disease without histamine H2-receptor antagonist or PPI (risk of bleeding)	58	6.42 (6.02, 6.81)
Central nervous system and psychotropic drugs
Long term (i.e. >1 month), long-acting benzodiazepines (risk of prolonged sedation, confusion, impaired balance, falls)	23	2.54 (2.38, 2.71)
Gastrointestinal system
PPI for peptic ulcer disease at maximum therapeutic dosage for >8 weeks† (dose reduction or earlier discontinuation indicated)	146	16.55 (15.27, 17.03)
Musculoskeletal system
NSAID with history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent histamine H2-receptor antagonist, PPI or misoprostol (risk of peptic ulcer relapse)	26	2.88 (2.69, 3.06)
Long term use of NSAID (i.e. >3 months) for pain relief (simple analgesics preferable)	62	6.86 (6.44, 7.27)
Analgesic drugs
Regular opiates for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation)	43	4.76 (4.46, 5.05)
Duplicate drug class prescription
All duplicates- two concurrent NSAIDs, SSRIs, loop diuretics and ACE inhibitors‡ (optimization of monotherapy within a single drug class)	39	4.31 (4.05, 4.58)